HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jim Sang Selected Research

STA 9090

6/2015The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
8/2014The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
2/2014Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
2/2014Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
1/2014Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
4/2013Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
1/2013Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
12/2012Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
12/2012Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
9/2012Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jim Sang Research Topics

Disease

16Neoplasms (Cancer)
11/2015 - 11/2006
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2015 - 09/2012
2Leukemia
04/2011 - 11/2010
1Colorectal Neoplasms (Colorectal Cancer)
08/2014
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2014
1Breast Neoplasms (Breast Cancer)
02/2014
1Melanoma (Melanoma, Malignant)
02/2014
1Inflammatory Breast Neoplasms
02/2014
1Neoplasm Metastasis (Metastasis)
01/2014
1Triple Negative Breast Neoplasms
01/2014
1Prostatic Neoplasms (Prostate Cancer)
01/2013
1Lung Neoplasms (Lung Cancer)
12/2012
1Adenocarcinoma of Lung
09/2012
1Oncogene Addiction
02/2012
1Wilms Tumor (Wilm's Tumor)
11/2010
1Myeloid Leukemia (Leukemia, Myelocytic)
11/2010

Drug/Important Bio-Agent (IBA)

13STA 9090IBA
06/2015 - 11/2010
6Heat-Shock Proteins (Heat-Shock Protein)IBA
08/2014 - 11/2006
6Molecular Chaperones (Chaperone, Molecular)IBA
07/2014 - 02/2012
5Proteins (Proteins, Gene)FDA Link
02/2014 - 11/2006
3Pharmaceutical PreparationsIBA
11/2015 - 12/2012
3tanespimycin (17AAG)IBA
09/2012 - 11/2006
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2014 - 02/2014
1STA-12-8666IBA
11/2015
1Irinotecan (Camptosar)FDA LinkGeneric
11/2015
1Topoisomerase I InhibitorsIBA
11/2015
1ErbB Receptors (EGF Receptor)IBA
06/2015
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2015
1Gefitinib (Iressa)FDA Link
06/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015
1ProdrugsIBA
08/2014
1Fluorouracil (Carac)FDA LinkGeneric
08/2014
1Capecitabine (Xeloda)FDA Link
08/2014
1Oncogene Proteins (Oncogene Protein)IBA
05/2014
1Lapatinib (GW572016)FDA Link
02/2014
1Proto-Oncogene Proteins B-rafIBA
02/2014
1tyrosine receptor (receptor, tyrosine)IBA
02/2014
1Hormones (Hormone)IBA
02/2014
1Transcription Factors (Transcription Factor)IBA
02/2014
1TAK 733IBA
02/2014
1VemurafenibIBA
02/2014
1Phosphotransferases (Kinase)IBA
04/2013
1CrizotinibIBA
04/2013
1Anaplastic Lymphoma KinaseIBA
04/2013
1Androgen Receptors (Androgen Receptor)IBA
01/2013
1AndrogensIBA
01/2013
1PlatinumIBA
12/2012
1Paclitaxel (Taxol)FDA LinkGeneric
12/2012
1Rifabutin (Ansamycin)FDA Link
12/2012
1Docetaxel (Taxotere)FDA Link
12/2012
1Taxoids (Taxanes)IBA
12/2012
1Phosphates (Orthophosphate)IBA
11/2012
12- amino- N- (2- methoxy- 5- (5- (3,4,5- trimethoxyphenyl)isoxazol- 4- yl)phenyl)- 3- phenylpropanamideIBA
11/2012
1TubulinIBA
11/2012
1fosbretabulin (combretastatin A4)IBA
11/2012
1geldanamycinIBA
09/2012
1Janus KinasesIBA
04/2011
1Bortezomib (Velcade)FDA Link
11/2006
1Proteasome InhibitorsIBA
11/2006
1Biological ProductsIBA
11/2006

Therapy/Procedure

8Therapeutics
06/2015 - 11/2010
3Drug Therapy (Chemotherapy)
01/2014 - 11/2010